Jiangsu Lanfeng Bio-chemical Co (002513) Fair Value & Analysis
Basic Materials · CN · Market cap 2.0B CNY
Fair value as of: Jul 22, 2026
From 4 valuation models · updated today
Fair value updated Jul 22, 2026, revised from ¥0.3500 to ¥1.49 (+325.7%) since Jun 25, 2026. Share price −14.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥4.43 – ¥10.40 · fair‑value band ¥0.7600 – ¥2.24 · the ¥4.43 price screens above the ¥1.49 fair value. As of Jul 22, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jiangsu Lanfeng Bio-chemical Co (002513) currently trades at ¥4.43, while our model-based Fair Value estimate is ¥1.49, implying the stock looks roughly 66.4% overvalued today. We read business quality at 31/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Jiangsu Lanfeng Bio-chemical Co generated revenue of 2.5B CNY at a net margin of -7.5%. Revenue grew 19.9% year over year. It earns a return on equity of -83.9%. Net debt stands at 194M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥0.7600 (bear case) to ¥2.24 (bull case); at ¥4.43, the current price sits above that range. The share trades about 61% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -21% fair-value upside, at -66%, 002513 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 22, 2026. TTM = trailing twelve months.
About the company
Jiangsu Lanfeng Bio-chemical Co.,Ltd researches, develops, produces, and sells pesticides, fungicides, insecticides, herbicides, and fine chemical intermediates in China and internationally. It offers carbendazim, thiophanate-methyl, cycloazinone, carbosulfan butyl, sulfuric acid, and surfactant. Jiangsu Lanfeng Bio-chemical Co.,Ltd was founded in 1976 and is based in Xinyi, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangsu Lanfeng Bio-chemical Co reported revenue of ¥2.3B in FY2025 versus ¥1.4B in FY2021, a compound +12.9%/yr. Reported net income was −¥191M in FY2025.
Is 002513 fairly valued? → Check now
Similar stocks
10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $77.46 | $39.29 | -49% |
| Nutrien Ltd NTR | $65.03 | $50.33 | -23% |
| Qinghai Salt Lake Industry Co 000792 | ¥29.45 | ¥21.15 | -28% |
| CF Industries Holdings C1FI34 | R$533.71 | R$176.57 | -67% |
| Yara International ASA YRAIF | $47.55 | $68.66 | +44% |
| Yunnan Yuntianhua Co 600096 | ¥32.53 | ¥42.12 | +29% |
| The Mosaic Company MOS | $21.25 | $28.92 | +36% |
| Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 | ¥48.55 | ¥38.01 | -22% |
| Coromandel International Limited COROMANDEL | ₹1,797 | ₹1,414 | -21% |
| UPL Limited UPL | ₹611.00 | ₹655.81 | +7% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Jiangsu Lanfeng Bio-chemical Co (002513) undervalued?
What is the fair value of 002513?
What is the quality score of 002513?
What is the revenue of Jiangsu Lanfeng Bio-chemical Co (002513)?
What is the net profit margin of 002513?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Jiangsu Lanfeng Bio-chemical Co analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.